CY1489A - Improvements in or relating to novel difluoro antiviral agents - Google Patents

Improvements in or relating to novel difluoro antiviral agents

Info

Publication number
CY1489A
CY1489A CY1489A CY148989A CY1489A CY 1489 A CY1489 A CY 1489A CY 1489 A CY1489 A CY 1489A CY 148989 A CY148989 A CY 148989A CY 1489 A CY1489 A CY 1489A
Authority
CY
Cyprus
Prior art keywords
relating
antiviral agents
novel difluoro
difluoro
novel
Prior art date
Application number
CY1489A
Other languages
English (en)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23881409&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1489(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of CY1489A publication Critical patent/CY1489A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/32—Oxygen atoms
    • C07D307/33—Oxygen atoms in position 2, the oxygen atom being in its keto or unsubstituted enol form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D317/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H11/00—Compounds containing saccharide radicals esterified by inorganic acids; Metal salts thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H5/00—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium
    • C07H5/02—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium to halogen
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Furan Compounds (AREA)
CY1489A 1983-03-10 1989-12-08 Improvements in or relating to novel difluoro antiviral agents CY1489A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/473,883 US4526988A (en) 1983-03-10 1983-03-10 Difluoro antivirals and intermediate therefor

Publications (1)

Publication Number Publication Date
CY1489A true CY1489A (en) 1989-12-08

Family

ID=23881409

Family Applications (1)

Application Number Title Priority Date Filing Date
CY1489A CY1489A (en) 1983-03-10 1989-12-08 Improvements in or relating to novel difluoro antiviral agents

Country Status (36)

Country Link
US (5) US4526988A (fr)
EP (1) EP0122707B1 (fr)
JP (2) JPS59175498A (fr)
KR (1) KR860001283B1 (fr)
AR (1) AR243533A1 (fr)
AT (1) ATE29726T1 (fr)
AU (1) AU565856B2 (fr)
BG (1) BG40814A3 (fr)
CA (2) CA1218647A (fr)
CS (1) CS246075B2 (fr)
CY (1) CY1489A (fr)
DD (1) DD216468A5 (fr)
DE (2) DE3466224D1 (fr)
DK (2) DK162529C (fr)
ES (1) ES530364A0 (fr)
FI (1) FI77870C (fr)
GB (2) GB2136425B (fr)
GR (1) GR81845B (fr)
HK (1) HK44989A (fr)
HU (1) HU193893B (fr)
IE (1) IE57071B1 (fr)
IL (2) IL80463A (fr)
KE (1) KE3874A (fr)
LU (1) LU88791I2 (fr)
MX (1) MX9203246A (fr)
MY (1) MY102025A (fr)
NL (1) NL950018I2 (fr)
NZ (1) NZ207358A (fr)
PH (2) PH23240A (fr)
PL (1) PL142437B1 (fr)
PT (1) PT78181B (fr)
RO (1) RO89963A (fr)
SG (1) SG21889G (fr)
SU (1) SU1442076A3 (fr)
UA (1) UA5955A1 (fr)
ZA (1) ZA841605B (fr)

Families Citing this family (241)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4526988A (en) * 1983-03-10 1985-07-02 Eli Lilly And Company Difluoro antivirals and intermediate therefor
ZA859008B (en) * 1984-12-04 1987-07-29 Lilly Co Eli The treatment of tumors in mammals
EP0184365B1 (fr) * 1984-12-04 1993-08-04 Eli Lilly And Company Traitement de tumeurs chez les mammifères
US4681873A (en) * 1985-07-29 1987-07-21 Warner-Lambert Company 4-amino-3-halo-2-pyridinone nucleoside and nucleotide compounds
CA1295998C (fr) * 1985-07-29 1992-02-18 Sai P. Sunkara Nucleosides et leur utilisation en tant qu'agents antineoplasiques
US4814438A (en) * 1986-12-24 1989-03-21 Eli Lilly And Company Immunoglobulin conjugates of 2',2'-difluronucleosides
US4994558A (en) * 1986-12-24 1991-02-19 Eli Lilly And Company Immunoglobulin conjugates
IL84842A0 (en) * 1986-12-24 1988-06-30 Lilly Co Eli Immunoglobulin conjugates
EP0277599A3 (fr) * 1987-01-30 1990-05-09 Asahi Glass Company Ltd. Dérivés de cyclopentane contenant du fluor et procédés pour leur préparation
CA1340645C (fr) * 1987-04-17 1999-07-13 Victor E. Marquez Didesoxynucleosides stables en milieu acide, actifs contre les effets cytopathiques du virus de l'immunoeficience humaine
DE3856527T2 (de) * 1987-08-28 2002-10-31 Eli Lilly And Co., Indianapolis Stereoselektives Verfahren zur Herstellung von geschützten 2',2'-difluorlactonen
US5223608A (en) * 1987-08-28 1993-06-29 Eli Lilly And Company Process for and intermediates of 2',2'-difluoronucleosides
US4965374A (en) * 1987-08-28 1990-10-23 Eli Lilly And Company Process for and intermediates of 2',2'-difluoronucleosides
US4914028A (en) * 1988-02-10 1990-04-03 Eli Lilly And Company Method of preparing beta-2',2'-difluoronucleosides
US4983724A (en) * 1988-02-16 1991-01-08 Eli Lilly And Company Inversion of 2,2-difluororibose to a 2,2-difluoroxylose and intermediates therefor
IL89258A0 (en) * 1988-02-16 1989-09-10 Lilly Co Eli 2',3'-dideoxy-2',2'-difluoro-nucleosides
US5644043A (en) * 1988-02-16 1997-07-01 Eli Lilly And Company 2',3'-dideoxy-2',2'-difluoronucleosides and intermediates
ATE128141T1 (de) * 1988-03-16 1995-10-15 Scripps Research Inst Als therapeutische mittel verwendbare substituierte adeninderivate.
US5057301A (en) * 1988-04-06 1991-10-15 Neorx Corporation Modified cellular substrates used as linkers for increased cell retention of diagnostic and therapeutic agents
JPH0232093A (ja) * 1988-06-08 1990-02-01 Merrell Dow Pharmaceut Inc 抗レトロウィルスジフルオロ化ヌクレオシド類
US4987224A (en) * 1988-08-02 1991-01-22 University Of Georgia Research Foundation, Inc. Method of preparation of 2',3'-dideoxynucleosides
US5157114A (en) * 1988-08-19 1992-10-20 Burroughs Wellcome Co. 2',3'-dideoxy-3'-fluoro-5-ethyngluridine
US4954623A (en) * 1989-03-20 1990-09-04 Eli Lilly And Company Recovery of difluoro sugar
CA2012129A1 (fr) * 1989-03-20 1990-09-20 Ramakrishnan Nagarajan Recuperation de sucre difluore
FI932871A (fi) * 1992-06-22 1993-12-23 Lilly Co Eli Stereoselektiv anjonglykosylationsprocess
US5594124A (en) * 1992-06-22 1997-01-14 Eli Lilly And Company Stereoselective glycosylation process for preparing 2'-Deoxy-2',2'-difluoropyrimidine nucleosides and 2'-deoxy-2'-fluoropyrimidine nucleosides and intermediates thereof
US5401838A (en) * 1992-06-22 1995-03-28 Eli Lilly And Company Stereoselective fusion glycosylation process for preparing 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides
US5821357A (en) * 1992-06-22 1998-10-13 Eli Lilly And Company Stereoselective glycosylation process for preparing 2'-deoxy-2',2'-difluoropurine and triazole nucleosides
US5606048A (en) * 1992-06-22 1997-02-25 Eli Lilly And Company Stereoselective glycosylation process for preparing 2'-Deoxy-2', 2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides
US5371210A (en) * 1992-06-22 1994-12-06 Eli Lilly And Company Stereoselective fusion glycosylation process for preparing 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides
US5401861A (en) * 1992-06-22 1995-03-28 Eli Lilly And Company Low temperature process for preparing alpha-anomer enriched 2-deoxy-2,2-difluoro-D-ribofuranosyl sulfonates
YU43193A (sh) * 1992-06-22 1997-01-08 Eli Lilly And Company 2'-deoksi-2',2'-difluoro(4-supstituisani)pirimidinski nukleozidi antivirusnog i antikancerogenog dejstva i međuproizvodi
US5256798A (en) * 1992-06-22 1993-10-26 Eli Lilly And Company Process for preparing alpha-anomer enriched 2-deoxy-2,2-difluoro-D-ribofuranosyl sulfonates
HU214030B (en) * 1992-06-22 1997-12-29 Lilly Co Eli Process for preparing alpha-anomer enriched 1-halogen-2-deoxy-2,2-difluoro-d-ribofuranosyl derivatives
US5426183A (en) * 1992-06-22 1995-06-20 Eli Lilly And Company Catalytic stereoselective glycosylation process for preparing 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides
US5252756A (en) * 1992-06-22 1993-10-12 Eli Lilly And Company Process for preparing beta-anomer enriched 2-deoxy-2,2-difluoro-D-ribofuranosyl-arylsulfonates
US5256797A (en) 1992-06-22 1993-10-26 Eli Lilly And Company Process for separating 2-deoxy-2,2-difluoro-D-ribofuranosyl alkylsulfonate anomers
US5424416A (en) * 1993-08-25 1995-06-13 Eli Lilly And Company Process for preparation of 2-deoxy-2,2-difluoro-D-ribofuranosyl-3,5-hydroxy protected-1-alkyl and aryl sulfonates and their use in preparation of 2',2'-difluoro-2'-deoxy nucleosides
US5480992A (en) * 1993-09-16 1996-01-02 Eli Lilly And Company Anomeric fluororibosyl amines
US5428176A (en) * 1994-04-14 1995-06-27 Eli Lilly And Company Process for preparing 2,2-difluoroketene silyl O,S-acetals and α,α-difluoro-β-silyloxy-1,3-dioxolane-4-propanoic acid O,S-esters
US5637688A (en) 1994-12-13 1997-06-10 Eli Lilly And Company Process for preparing 1-(2'-deoxy-2'-difluoro-d-ribofuranosyl)-4-aminopyrimidin-2-one hydrochloride
US5521294A (en) * 1995-01-18 1996-05-28 Eli Lilly And Company 2,2-difluoro-3-carbamoyl ribose sulfonate compounds and process for the preparation of beta nucleosides
US5559222A (en) * 1995-02-03 1996-09-24 Eli Lilly And Company Preparation of 1-(2'-deoxy-2',2'-difluoro-D-ribo-pentofuranosyl)-cytosine from 2-deoxy-2,2-difluoro-β-D-ribo-pentopyranose
US5633367A (en) * 1995-03-24 1997-05-27 Eli Lilly And Company Process for the preparation of a 2-substituted 3,3-difluorofuran
CA2171518A1 (fr) * 1995-03-24 1996-09-25 Douglas Patton Kjell Methode de preparation de 2,2'-anhydro- et 2' -ceto-1-(3',5'-di-o-protege-.beta.-d-arabinofuranosyl)nucleosides
US5756775A (en) * 1995-12-13 1998-05-26 Eli Lilly And Company Process to make α,α-difluoro-β-hydroxyl thiol esters
US6001994A (en) * 1995-12-13 1999-12-14 Eli Lilly And Company Process for making gemcitabine hydrochloride
AU1289697A (en) 1995-12-13 1997-07-03 Eli Lilly And Company Alpha, alpha-difluoro-beta-hydroxy thiol esters and their synthesis
US5808020A (en) * 1996-08-12 1998-09-15 Associated Universities, Inc. Optical reaction cell and light source for 18F! fluoride radiotracer synthesis
US6013790A (en) * 1996-09-25 2000-01-11 Board Of Regents University Of Nebraska-Lincoln Heavily fluorinated sugar analogs
JP2001518931A (ja) * 1997-03-24 2001-10-16 イーライ・リリー・アンド・カンパニー ジフルオロヌクレオシドホスホン酸とその誘導体
ES2276515T3 (es) * 1998-02-25 2007-06-16 Emory University 2'-fluoronucleosidos.
TW466112B (en) * 1998-04-14 2001-12-01 Lilly Co Eli Novel use of 2'-deoxy-2',2'-difluorocytidine for immunosuppressive therapy and pharmaceutical composition comprising the same
US6326507B1 (en) * 1998-06-19 2001-12-04 Trustees Of Dartmouth College Therapeutic compounds and methods of use
US20030008841A1 (en) * 2000-08-30 2003-01-09 Rene Devos Anti-HCV nucleoside derivatives
KR100600550B1 (ko) * 2000-10-20 2006-07-13 에자이 가부시키가이샤 질소 함유 방향환 유도체
US7435755B2 (en) * 2000-11-28 2008-10-14 The Trustees Of Dartmouth College CDDO-compounds and combination therapies thereof
US8481712B2 (en) 2001-01-22 2013-07-09 Merck Sharp & Dohme Corp. Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
WO2003059334A2 (fr) * 2001-10-25 2003-07-24 Eli Lilly And Company Gemcitabine pour traiter la variole
CA2472581C (fr) * 2002-01-15 2012-06-26 Trustees Of Dartmouth College Derives de bis-enone tricyclique et methodes d'utilisation
KR20040094692A (ko) * 2002-02-14 2004-11-10 파마셋, 리미티드 변형된 불소화 뉴클레오사이드 유사체
EP1604665B1 (fr) * 2003-03-10 2011-05-11 Eisai R&D Management Co., Ltd. Inhibiteur de kinase c-kit
WO2004105747A1 (fr) * 2003-05-20 2004-12-09 Aronex Pharmaceuticals, Inc Chimiotherapie combinee comprenant capecitabine et un complexe a base de platine liposomique
AU2003239510A1 (en) * 2003-05-20 2005-01-21 Aronex Pharmaceuticals, Inc. Combination chemotherapy comprising gemcitabine and a liposomal platinum complex
WO2005003147A2 (fr) * 2003-05-30 2005-01-13 Pharmasset, Inc. Analogues de nucleosides fluores modifies
US20060034943A1 (en) * 2003-10-31 2006-02-16 Technology Innovations Llc Process for treating a biological organism
US7683172B2 (en) * 2003-11-11 2010-03-23 Eisai R&D Management Co., Ltd. Urea derivative and process for preparing the same
WO2005076888A2 (fr) 2004-02-06 2005-08-25 Threshold Pharmaceuticals, Inc. Therapies anticancereuses
ATE507240T1 (de) * 2004-03-05 2011-05-15 Vegenics Pty Ltd Materialien und verfahren für wachstumsfaktorbindende konstrukte
US20050249667A1 (en) * 2004-03-24 2005-11-10 Tuszynski Jack A Process for treating a biological organism
EP2348029A1 (fr) * 2004-07-21 2011-07-27 Pharmasset, Inc. Preparation de pyrimidines et purines 2-desoxy-2-fluoro-d-ribofuranosyl substitues en alkyle et leurs dérives
CN101023094B (zh) * 2004-07-21 2011-05-18 法莫赛特股份有限公司 烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备
KR100578616B1 (ko) * 2004-07-23 2006-05-10 한미약품 주식회사 Ｄ-에리트로-2,2-다이플루오로-2-데옥시-1-옥소라이보스화합물의 제조방법
BRPI0513783A (pt) * 2004-07-29 2008-05-13 Hanmi Pharm Ind Co Ltd derivados 1-(alfa)-halo-2, 2-diflúor-2-desóxi-d-ribofuranose e processo para a sua preparação
EP1812457A1 (fr) * 2004-07-30 2007-08-01 Pharmaessentia Corp. SYNTHÈSE STÉRÉOSÉLECTIVE DE ß-NUCLÉOSIDES
SI3109244T1 (sl) 2004-09-14 2019-06-28 Gilead Pharmasset Llc Priprava 2'fluoro-2'-alkil-substituiranih ali drugih neobvezno substituiranih ribofuranozil pirimidinov in purinov in njihovih derivatov
WO2006030826A1 (fr) * 2004-09-17 2006-03-23 Eisai R & D Management Co., Ltd. Composition medicamenteuse
US20060089328A1 (en) * 2004-10-22 2006-04-27 Edgar Schridde Ready-to-use gemcitabine solutions
US7563570B2 (en) * 2004-10-29 2009-07-21 Pangaea Biotech Method of determining a chemotherapeutic regimen for non small cell lung cancer based on BRCA1 expression
JP2007522151A (ja) * 2004-12-08 2007-08-09 シコール インコーポレイティド ジフルオロヌクレオシド及びその調製方法
ATE405573T1 (de) * 2004-12-17 2008-09-15 Lilly Co Eli Amid-prodrug von gemcitabin, zusammensetzungen und verwendung damit
WO2006077424A1 (fr) 2005-01-21 2006-07-27 Astex Therapeutics Limited Composes pharmaceutiques
KR20070112774A (ko) * 2005-03-04 2007-11-27 다브르 파마 리미티드 베타―아노머가 많은２１데옥시，２１，２１－디플루오로－ｄ－리보푸라노실뉴클레오시드의 제조를 위한 중간체 및 제조 방법
US7485716B2 (en) * 2005-05-02 2009-02-03 Pharmaessentia Corp. Stereoselective synthesis of β-nucleosides
AU2011202539B2 (en) * 2005-06-03 2012-07-05 Scinopharm Taiwan, Ltd. Process of making an alpha-anomer enriched 2-deoxy-2,2-difluoro-d-ribofuranosyl sulfonate and use thereof for making a beta nucleoside
NZ563995A (en) * 2005-06-03 2010-01-29 Scinopharm Taiwan Ltd Process of making an alpha-anomer enriched 2-deoxy-2,2-difluoro-d-ribofuranosyl sulfonate and use thereof for making a beta nucleoside
SG164368A1 (en) 2005-07-18 2010-09-29 Bipar Sciences Inc Treatment of cancer
AT502221A1 (de) * 2005-07-20 2007-02-15 Pharmacon Forschung & Beratung Gmbh Homogemcitabine, verfahren zu ihrer herstellung sowie deren verwendung
WO2007015569A1 (fr) * 2005-08-01 2007-02-08 Eisai R & D Management Co., Ltd. Procédé de prédiction de l’efficacité d’un inhibiteur de vascularisation
EP1925676A4 (fr) 2005-08-02 2010-11-10 Eisai R&D Man Co Ltd Procédé d'analyse de l' effet d 'un inhibiteur de vascularisation
WO2007015257A2 (fr) * 2005-08-04 2007-02-08 Hetero Drugs Limited Procede de preparation de gemcitabine utilisant de nouveaux intermediaires
CN102716490A (zh) * 2005-09-01 2012-10-10 卫材R&D管理有限公司 药物组合物的崩解性的改善方法
EP1940859A1 (fr) 2005-10-28 2008-07-09 Arch Pharmalabs Limited Procede ameliore de preparation de gemcitabine hydrochlorure
JPWO2007052849A1 (ja) 2005-11-07 2009-04-30 エーザイ・アール・アンド・ディー・マネジメント株式会社 血管新生阻害物質とｃ−ｋｉｔキナーゼ阻害物質との併用
US20090247576A1 (en) * 2005-11-22 2009-10-01 Eisai R & D Management Co., Ltd. Anti-tumor agent for multiple myeloma
JP2009519325A (ja) * 2005-12-14 2009-05-14 ドン−エー ファーム．カンパニー リミテッド ２’、２’−ジフルオロヌクレオシドと中間体の製造プロセス
CA2640463A1 (fr) * 2006-02-06 2007-10-18 Dr. Reddy's Laboratories Ltd. Preparation de gemcitabine
KR20080099263A (ko) * 2006-02-07 2008-11-12 케마지스 리미티드 젬시타빈 및 관련된 중간체의 제조 방법
US20070249823A1 (en) * 2006-04-20 2007-10-25 Chemagis Ltd. Process for preparing gemcitabine and associated intermediates
WO2007136103A1 (fr) * 2006-05-18 2007-11-29 Eisai R & D Management Co., Ltd. Agent antitumoral destiné au cancer de la thyroïde
EP2044939A1 (fr) * 2006-06-29 2009-04-08 Eisai R&D Management Co., Ltd. Agent thérapeutique contre la fibrose hépatique
US20100160442A1 (en) * 2006-07-18 2010-06-24 Ossovskaya Valeria S Formulations for cancer treatment
KR100741310B1 (ko) * 2006-08-01 2007-08-01 (주) 유일팜테크 젬시타빈의 합성에 유용한 신규한나프탈렌-2-카르복실레이트 유도체와 그의 제조방법
WO2008026748A1 (fr) * 2006-08-28 2008-03-06 Eisai R & D Management Co., Ltd. Agent antitumoral pour cancer gastrique non différencié
WO2008033466A2 (fr) * 2006-09-14 2008-03-20 Combinatorx (Singapore) Pre. Ltd. Compositions et procédés pour le traitement de maladies virales
WO2008044045A1 (fr) 2006-10-12 2008-04-17 Astex Therapeutics Limited Combinaisons pharmaceutiques
US8916552B2 (en) 2006-10-12 2014-12-23 Astex Therapeutics Limited Pharmaceutical combinations
RU2639543C9 (ru) 2006-10-27 2018-06-14 Дженентек, Инк. Антитела и иммуноконъюгаты и их применения
CA2670099A1 (fr) * 2006-11-17 2008-05-29 Trustees Of Dartmouth College Synthese et activites biologiques de nouveaux composes tricycliques-bis-enones (tbe)
WO2008064132A2 (fr) * 2006-11-17 2008-05-29 Trustees Of Dartmouth College Triterpénoïdes synthétiques et bis-énones tricycliques pour une utilisation dans la stimulation de croissance osseuse et cartilagineuse
US8921340B2 (en) 2006-11-17 2014-12-30 Trustees Of Dartmouth College Methods for using synthetic triterpenoids in the treatment of bone or cartilage diseases or conditions
AU2008205847A1 (en) 2007-01-19 2008-07-24 Eisai R & D Management Co., Ltd. Composition for treatment of pancreatic cancer
CN101600694A (zh) * 2007-01-29 2009-12-09 卫材R&D管理有限公司 未分化型胃癌治疗用组合物
US7994310B2 (en) * 2007-03-23 2011-08-09 Dongwoo Syntech Co., Ltd. Process for preparing 2′-deoxy-2′, 2′-difluorocytidine
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
CN101024667B (zh) * 2007-03-30 2011-01-26 湖北益泰药业有限公司 盐酸吉西他宾的合成方法
US8765690B2 (en) * 2007-04-05 2014-07-01 Threshold Pharmaceuticals, Inc. Treatment of cancer with glufosfamide in patients not receiving insulin therapy
US20080262215A1 (en) * 2007-04-23 2008-10-23 Chemagis Ltd. Gemcitabine production process
CN100475832C (zh) * 2007-05-31 2009-04-08 南京卡文迪许生物工程技术有限公司 一种新颖的高立体选择性合成吉西他滨工艺及中间体
EP2202297B1 (fr) * 2007-07-18 2014-05-14 Genelux Corporation Utilisation d'un agent chemothérapeutique dans la préparation d'un médicament pour le traitement ou l'amélioration d'effets collatéraux des thérapies avec virus oncolytique
US20090048205A1 (en) * 2007-08-15 2009-02-19 Colin Meyer Combination therapy with synthetic triterpenoids and gemcitabine
TWI436775B (zh) * 2007-08-24 2014-05-11 Oncotherapy Science Inc 以抗原胜肽合併化療藥劑治療胰臟癌
US20090069354A1 (en) * 2007-09-12 2009-03-12 Protia, Llc Deuterium-enriched gemcitabine
WO2009042064A2 (fr) 2007-09-21 2009-04-02 Nektar Therapeutics Al, Corporation Conjugués nucléoside phosphate oligomères
JP4253357B1 (ja) 2007-09-27 2009-04-08 株式会社湯山製作所 手撒き薬剤供給装置、薬剤の手撒き方法、及び、薬剤分包装置
JO2778B1 (en) 2007-10-16 2014-03-15 ايساي انك Certain vehicles, installations and methods
CN101883570B (zh) * 2007-11-06 2013-06-19 药华医药股份有限公司 β-核苷的新颖合成
KR101502267B1 (ko) 2007-11-09 2015-03-18 페레그린 파마수티컬즈, 인크 항-ｖｅｇｆ 항체 조성물 및 방법
CA2704000C (fr) 2007-11-09 2016-12-13 Eisai R&D Management Co., Ltd. Combinaison d'une substance antiangiogenique et d'un complexe de platine antitumoral
CN101918003A (zh) * 2007-11-12 2010-12-15 彼帕科学公司 单独使用parp抑制剂或与抗肿瘤剂组合治疗子宫癌和卵巢癌
TW200942231A (en) 2008-01-11 2009-10-16 Reata Pharmaceuticals Inc Synthetic triterpenoids and methods of use in the treatment of disease
CA2713930A1 (fr) * 2008-01-29 2009-08-06 Eisai R & D Management Co., Ltd. Utilisation combinee d'un inhibiteur de l'angiogenese et d'un taxane
NZ588710A (en) 2008-04-18 2012-12-21 Reata Pharmaceuticals Inc Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at C-17
CN104250280A (zh) * 2008-04-18 2014-12-31 里亚塔医药公司 抗氧化剂炎症调节剂:c-17同系化齐墩果酸衍生物
WO2009129545A1 (fr) 2008-04-18 2009-10-22 Reata Pharmaceuticals, Inc. Modulateurs d'inflammation antioxydants: dérivés d'acide oléanolique présentant une saturation dans l'anneau c
TW201004627A (en) * 2008-04-18 2010-02-01 Reata Pharmaceuticals Inc Antioxidant inflammation modulators: novel derivatives of oleanolic acid
JP5564490B2 (ja) 2008-04-18 2014-07-30 リアタ ファーマシューティカルズ インコーポレイテッド 抗炎症性ファルマコアを含む化合物および使用法
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
CA2727813A1 (fr) * 2008-06-12 2009-12-17 Scinopharm Taiwan, Ltd. Polymorphes cristallins de la base gemcitabine
JP5758801B2 (ja) 2008-07-22 2015-08-05 トラスティーズ・オブ・ダートマス・カレッジＴｒｕｓｔｅｅｓ ｏｆ Ｄａｒｔｍｏｕｔｈ Ｃｏｌｌｅｇｅ 単環式シアノエノンおよびその使用方法説明
US20110207680A1 (en) * 2008-08-13 2011-08-25 Curd John G Administration of Glufosfamide For The Treatment of Cancer
WO2010049947A2 (fr) * 2008-10-28 2010-05-06 Accrete Pharmaceutical Private Limited Préparation de gemcitabine et de ses intermédiaires
WO2010075517A2 (fr) 2008-12-23 2010-07-01 Pharmasset, Inc. Analogues de nucléoside
CL2009002207A1 (es) 2008-12-23 2011-02-18 Gilead Pharmasset Llc Compuestos derivados de 3-hidroxi-5-(9h-purin-9-il)tetrahidrofuran-2-il, inhibidor de la replicacion de arn viral dependiente de arn; composicion farmaceutica; uso para el tratamiento de hepatitis c.
SG172363A1 (en) 2008-12-23 2011-07-28 Pharmasset Inc Synthesis of purine nucleosides
US8329666B2 (en) * 2009-04-06 2012-12-11 Eisai Inc. Compositions and methods for treating cancer
CA2757743C (fr) * 2009-04-06 2017-10-10 Eisai Inc. Derives de (2'-desoxy-ribofuranosyl)-1,3,4,7-tetrahydro-(1,3) diazepine-2-0ne pour le traitement du cancer
CA2757745C (fr) * 2009-04-06 2018-02-13 Eisai Inc. Association comprenant des medicaments antineoplasiques a base de cytidine et un inhibiteur de la cytidine desaminase et utilisation de cette association dans le traitement du cancer
US8609631B2 (en) 2009-04-06 2013-12-17 Eisai Inc. Compositions and methods for treating cancer
US20100273730A1 (en) * 2009-04-27 2010-10-28 Innopharmax, Inc. Self-emulsifying pharmaceutical compositions of hydrophilic drugs and preparation thereof
GB0907551D0 (en) 2009-05-01 2009-06-10 Univ Dundee Treatment or prophylaxis of proliferative conditions
TWI583692B (zh) 2009-05-20 2017-05-21 基利法瑪席特有限責任公司 核苷磷醯胺
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
EP2459170A2 (fr) 2009-07-31 2012-06-06 Astron Research Limited Composition stable pour injection de gemcitabine prête à l'emploi
WO2011028638A1 (fr) 2009-09-04 2011-03-10 Schering Corporation Modulateurs de points de contrôle du cycle cellulaire et leur utilisation en combinaison avec des inhibiteurs de kinase de point de contrôle
EP2536720A1 (fr) 2010-02-18 2012-12-26 Centro Nacional de Investigaciones Oncológicas (CNIO) Composés bicycliques destinés à être utilisés en tant qu'inhibiteurs de kinases
ES2575160T3 (es) 2010-03-15 2016-06-24 The Board Of Trustees Of The University Of Illinois Inhibidores de las interacciones que unen la subunidad alfa de la beta integrina-proteína G
US8563530B2 (en) 2010-03-31 2013-10-22 Gilead Pharmassel LLC Purine nucleoside phosphoramidate
AP3515A (en) 2010-03-31 2016-01-11 Gilead Pharmasset Llc Nucleoside phosphoramidates
WO2011143593A1 (fr) 2010-05-14 2011-11-17 Cornerstone Pharmaceuticals, Inc. Conjugués de dérivé d'acide lipoïque et d'agent antiprolifératif et leurs utilisations médicales
WO2011143590A1 (fr) 2010-05-14 2011-11-17 Cornerstone Pharmaceuticals, Inc. Compositions et méthodes de polythérapie utilisant dérivés d'acide lipoïque et agent antiprolifératif
MX2012014776A (es) 2010-06-25 2013-01-29 Eisai R&D Man Co Ltd Agente antitumoral que emplea compuestos con efecto inhibidor de cinasas combinados.
CN103209987B (zh) 2010-09-22 2017-06-06 艾丽奥斯生物制药有限公司 取代的核苷酸类似物
WO2012069972A1 (fr) 2010-11-19 2012-05-31 Piramal Life Sciences Limited Combinaison pharmaceutique pour le traitement du cancer du sein
JP6069215B2 (ja) 2010-11-30 2017-02-01 ギリアド ファーマセット エルエルシー 化合物
WO2012087943A2 (fr) 2010-12-20 2012-06-28 The Regents Of The University Of Michigan Inhibiteurs de l'interaction de liaison entre le récepteur du facteur de croissance épidermique et la protéine de choc thermique 90
CN102153602B (zh) * 2011-02-24 2013-11-06 中国农业大学 呋喃糖基修饰的1,3,4-噻二唑衍生物及其制备方法与作为杀菌剂的应用
CN102153601A (zh) * 2011-02-26 2011-08-17 湖南欧亚生物有限公司 一种高选择性的制备盐酸吉西他滨以及其中间体的方法
TW201242597A (en) 2011-03-14 2012-11-01 Piramal Life Sciences Ltd A synergistic pharmaceutical combination for the treatment of pancreatic cancer
SG194045A1 (en) 2011-04-01 2013-11-29 Genentech Inc Combinations of akt inhibitor compounds and abiraterone, and methods of use
US8765933B2 (en) 2011-04-07 2014-07-01 Pharmaessentia Corp. Asynthesis of β-nucleosides
KR20130138840A (ko) 2011-04-13 2013-12-19 머크 샤프 앤드 돔 코포레이션 2''-치환된 뉴클레오시드 유도체 및 바이러스성 질환의 치료를 위한 그의 사용 방법
JP2014511875A (ja) 2011-04-13 2014-05-19 メルク・シャープ・アンド・ドーム・コーポレーション ２’−シアノ置換ヌクレオシド誘導体およびウイルス疾患の治療のためのその使用方法
EP2697242B1 (fr) 2011-04-13 2018-10-03 Merck Sharp & Dohme Corp. Dérivés de nucléosides à substitution 2'-azido et leurs procédés d'utilisation pour le traitement de maladies virales
AU2012246490B2 (en) 2011-04-18 2016-08-04 Eisai R&D Management Co., Ltd. Therapeutic agent for tumor
EP2714937B1 (fr) 2011-06-03 2018-11-14 Eisai R&D Management Co., Ltd. Biomarqueurs pour la prédiction et l'estimation de la sensibilité de sujets atteints d'un cancer de la thyroïde et du rein vis-à-vis de composés lenvatinib
CN102453064B (zh) * 2011-06-30 2014-07-09 江苏豪森药业股份有限公司 制备吉西他滨盐酸盐的方法
US9408863B2 (en) 2011-07-13 2016-08-09 Merck Sharp & Dohme Corp. 5′-substituted nucleoside analogs and methods of use thereof for the treatment of viral diseases
US9416154B2 (en) 2011-07-13 2016-08-16 Merck Sharp & Dohme Corp. 5′-substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
PL2750683T3 (pl) 2011-10-03 2018-10-31 Mx Adjuvac Ab Nanocząsteczki, sposób ich otrzymywania i ich zastosowanie jako nośnik dla związków amfipatycznych cząsteczek hydrofobowych w dziedzinach medycyny włączając leczenie raka i związki powiązane z żywnością
CN102417533A (zh) * 2011-10-28 2012-04-18 江苏正大清江制药有限公司 盐酸吉西他滨的合成方法
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
NO2755614T3 (fr) 2012-01-03 2018-03-31
WO2013142124A1 (fr) 2012-03-21 2013-09-26 Vertex Pharmaceuticals Incorporated Formes solides d'un promédicament nucléotidique thiophosphoramidate
US9012427B2 (en) 2012-03-22 2015-04-21 Alios Biopharma, Inc. Pharmaceutical combinations comprising a thionucleotide analog
JP6042527B2 (ja) 2012-04-04 2016-12-14 ハロザイム インコーポレイテッド 抗ヒアルロナン剤と腫瘍標的タキサンの組み合わせ治療
US8921419B2 (en) 2012-05-08 2014-12-30 Trustees Of Dartmouth College Triterpenoids and compositions containing the same
AU2013266393B2 (en) 2012-05-22 2017-09-28 Idenix Pharmaceuticals Llc D-amino acid compounds for liver disease
NZ702244A (en) 2012-06-08 2017-06-30 Hoffmann La Roche Mutant selectivity and combinations of a phosphoinositide 3 kinase inhibitor compound and chemotherapeutic agents for the treatment of cancer
WO2014006124A1 (fr) 2012-07-04 2014-01-09 F. Hoffmann-La Roche Ag Conjugués anticorps-antigène liés par covalence
EP2711008A1 (fr) 2012-09-19 2014-03-26 Institut Univ. de Ciència i Tecnologia, S.A. N6,N6-dimethyladenosine destiné à être utilisé dans le traitement ou la prévention du cancer du sein primitif et métastatique
EP2711009A1 (fr) 2012-09-19 2014-03-26 Institut Univ. de Ciència i Tecnologia, S.A. Composés destinés à être utilisés dans le traitement ou la prévention du cancer primitif et métastatique du sein et de la prostate
EP2711007A1 (fr) 2012-09-19 2014-03-26 Institut Univ. de Ciència i Tecnologia, S.A. 4-Aminopyrazolo[3,4-d]pyrimidine destiné à être utilisé dans le traitement ou la prévention du cancer du sein et de la prostate primitif et métastatique
US10513534B2 (en) 2012-10-08 2019-12-24 Idenix Pharmaceuticals Llc 2′-chloro nucleoside analogs for HCV infection
US9757432B2 (en) 2012-11-14 2017-09-12 Ohio State Innovation Foundation Materials and methods useful for treating glioblastorna
KR20150098605A (ko) 2012-12-21 2015-08-28 에자이 알앤드디 매니지먼트 가부시키가이샤 퀴놀린 유도체의 비정질 형태 및 그의 제조방법
WO2014163558A1 (fr) 2013-04-01 2014-10-09 Moreinx Ab Nanoparticules, constituées de stérol et de saponine de quillaja saponaria molina, leur procédé de préparation et leur utilisation comme support pour des molécules amphipathiques ou hydrophobes dans le domaine médical, notamment pour le traitement du cancer, et composés alimentaires
JP6411379B2 (ja) 2013-05-14 2018-10-24 エーザイ・アール・アンド・ディー・マネジメント株式会社 レンバチニブ化合物に対する子宮内膜がん対象の応答性を予測及び評価するためのバイオマーカー
JP6476591B2 (ja) * 2013-06-05 2019-03-06 セントラル硝子株式会社 （２Ｒ）−２−フルオロ−２−Ｃ−メチル−Ｄ−リボノ−γ−ラクトン類の製造方法
ES2582339T3 (es) * 2013-07-10 2016-09-12 Asteriapharma Gmbh Composiciones que comprenden oligómeros de gemcitabina para su uso en terapia
US20160158253A1 (en) * 2013-07-26 2016-06-09 Threshold Pharmaceuticals, Inc. Treatment of pancreatic cancer with a combination of a hypoxia-activated prodrug and a taxane
ES2900570T3 (es) 2013-08-27 2022-03-17 Gilead Pharmasset Llc Formulación de combinación de dos compuestos antivirales
MY176465A (en) 2013-10-29 2020-08-11 Otsuka Pharma Co Ltd Synthetic route to 2?-deoxy-2?,2?-difluorotetrahydrouridines
US10080807B2 (en) 2014-06-09 2018-09-25 Lipomedix Pharmaceuticals Ltd. Combination chemotherapy comprising a liposomal prodrug of mitomycin C
BR112016029935A2 (pt) 2014-06-26 2017-10-31 Hoffmann La Roche ?anticorpos anti-brdu, complexo, formulação farmacêutica e uso de anticorpo?
ES2926687T3 (es) 2014-08-28 2022-10-27 Eisai R&D Man Co Ltd Derivado de quinolina muy puro y método para su producción
WO2016123143A1 (fr) 2015-01-26 2016-08-04 The University Of Chicago Lymphocytes t à récepteur d'antigène chimérique (car) reconnaissant le récepteur il 13rα2 spécifique au cancer
US10308719B2 (en) 2015-01-26 2019-06-04 The University Of Chicago IL13Rα2 binding agents and use thereof in cancer treatment
US20180028662A1 (en) 2015-02-25 2018-02-01 Eisai R&D Management Co., Ltd. Method for Suppressing Bitterness of Quinoline Derivative
US20180044368A1 (en) * 2015-02-25 2018-02-15 Ligand Pharmaceuticals, Inc. Gemcitabine derivatives
CA2978226A1 (fr) 2015-03-04 2016-09-09 Merck Sharpe & Dohme Corp. Association d'un antagoniste de pd-1 et d'un inhibiteur des tyrosines kinases vegfr/fgfr/ret pour traiter le cancer
CA2988707C (fr) 2015-06-16 2023-10-10 Eisai R&D Management Co., Ltd. Combinaison de proteine se liant au cre/inhibiteur de catenine et d'un inhibiteur de point de controle immunitaire servant au traitement du cancer
EP3344642A1 (fr) * 2015-09-02 2018-07-11 AbbVie Inc. Dérivés anti-viraux de tétrahydrofurane
WO2017060661A1 (fr) * 2015-10-05 2017-04-13 Nucana Biomed Limited Polythérapie
WO2017098252A1 (fr) 2015-12-11 2017-06-15 Nucana Biomed Limited Synthèse diastéréosélective de dérivés de phosphate et du promédicament de gemcitabine nuc-1031
IL261721B (en) 2016-03-15 2022-07-01 Oryzon Genomics Sa Combinations of lsd1 inhibitors for use in the treatment of solid tumors
US11246905B2 (en) 2016-08-15 2022-02-15 President And Fellows Of Harvard College Treating infections using IdsD from Proteus mirabilis
WO2018094406A1 (fr) 2016-11-21 2018-05-24 Bexion Pharmaceuticals, Inc. Traitements combinés comprenant sapc-dops pour le traitement du cancer du pancréas
US11034667B2 (en) 2017-01-09 2021-06-15 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease
US11584733B2 (en) 2017-01-09 2023-02-21 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease
JP7247101B2 (ja) 2017-04-03 2023-03-28 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Ｓｔｅａｐ－１に結合する抗体
CN110831605A (zh) 2017-04-26 2020-02-21 托马斯·I.·卡尔曼 多靶标的核苷衍生物
CA3071599A1 (fr) 2017-08-07 2019-02-14 Amgen Inc. Traitement du cancer du sein triple negatif ou du cancer colorectal comportant des metastases hepatiques par un anticorps anti-pd-l1 et un virus oncolytique
EP4435009A2 (fr) 2017-09-18 2024-09-25 The Regents of the University of California Anticorps anti-claudine6 et méthodes de traitement du cancer
US10435429B2 (en) 2017-10-03 2019-10-08 Nucorion Pharmaceuticals, Inc. 5-fluorouridine monophosphate cyclic triester compounds
CN112004537A (zh) 2018-01-09 2020-11-27 穿梭药业公司 用于治疗人疾病的选择性组蛋白去乙酰化酶抑制剂
CA3088287A1 (fr) 2018-01-10 2019-07-18 Nucorion Pharmaceuticals, Inc. Composes de phosphore(n)amidatacetal et phosph(on)atalcetal
US11427550B2 (en) 2018-01-19 2022-08-30 Nucorion Pharmaceuticals, Inc. 5-fluorouracil compounds
AU2019216531A1 (en) 2018-02-02 2020-09-24 Maverix Oncology, Inc. Small molecule drug conjugates of gemcitabine monophosphate
TW202002952A (zh) 2018-03-15 2020-01-16 美商艾伯維有限公司 用於治療胰臟癌之abbv-621與抗癌劑之組合
WO2019222435A1 (fr) 2018-05-16 2019-11-21 Halozyme, Inc. Procédés de sélection de sujets pour une polythérapie anticancéreuse avec un ph20 soluble conjugué à un polymère
WO2020044252A1 (fr) 2018-08-31 2020-03-05 Novartis Ag Régimes posologiques pour anticorps anti-m-csf et utilisations associées
EP3669890A1 (fr) 2018-12-18 2020-06-24 Croda International PLC Nanoparticules filamenteuses ayant un effet d'adjuvant de vaccin
US20220087975A1 (en) 2019-01-11 2022-03-24 Lipomedix Pharmaceuticals Ltd. Liposome composition comprising liposomal prodrug of mitomycin c and method of manufacture
CA3134056A1 (fr) 2019-03-20 2020-09-24 The Regents Of The University Of California Anticorps de claudin-6 bispecifiques
WO2020191342A1 (fr) 2019-03-20 2020-09-24 The Regents Of The University Of California Anticorps anti-claudine-6 et conjugués de médicaments
BR112021021663A2 (pt) 2019-04-30 2022-05-17 Inst De Medicina Molecular Joao Lobo Antunes Inibidores da via rank em combinação com inibidores de cdk
US20220305081A1 (en) 2019-06-24 2022-09-29 Amgen Inc. Inhibitions of sirp-gamma for cancer treatment
US12110311B2 (en) 2019-07-17 2024-10-08 Nucorion Pharmaceuticals, Inc. Cyclic deoxyribonucleotide compounds
US20230218644A1 (en) 2020-04-16 2023-07-13 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus
WO2021216427A1 (fr) 2020-04-21 2021-10-28 Ligand Pharmaceuticals, Inc. Composés de promédicaments nucléotidiques

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2359096A (en) * 1941-03-21 1944-09-26 Lilly Co Eli beta-substituted-delta alpha, beta-gamma-butyrolactones and beta-substituted - beta - hydroxy-gamma-butyrolactones and methods of preparing them
US2359208A (en) * 1941-03-21 1944-09-26 Lilly Co Eli beta-substituted-delta alpha,beta-gamma-butyrolactones and beta-substituted-beta-hydroxy-gamma-butyrolactones and the methods of preparing them
FR1362039A (fr) * 1963-04-17 1964-05-29 Ct D Etudes Experimentales Et Nouveau procédé de préparation du semi-aldéhyde succinique
US3282921A (en) * 1964-06-04 1966-11-01 Syntex Corp Halo-deoxynucleosides and processes for the preparation thereof
US3870700A (en) * 1973-05-29 1975-03-11 Miles Lab 2-halogeno-2-deoxy-5-(substituted)uridines
US4211773A (en) * 1978-10-02 1980-07-08 Sloan Kettering Institute For Cancer Research 5-Substituted 1-(2'-Deoxy-2'-substituted-β-D-arabinofuranosyl)pyrimidine nucleosides
US4352795A (en) * 1981-01-29 1982-10-05 Warner-Lambert Company 7-β-D-Arabinofuranosyl-7H-pyrrolo[2,3-d]pyrimidine compounds and methods for their production
FR2531962B1 (fr) * 1982-08-17 1986-11-14 Sandoz Sa Nouveaux derives de la desoxyuridine, leur preparation et leur utilisation comme medicaments
US4526988A (en) * 1983-03-10 1985-07-02 Eli Lilly And Company Difluoro antivirals and intermediate therefor
US4625020A (en) * 1983-11-18 1986-11-25 Bristol-Myers Company Nucleoside process
CA1295998C (fr) * 1985-07-29 1992-02-18 Sai P. Sunkara Nucleosides et leur utilisation en tant qu'agents antineoplasiques

Also Published As

Publication number Publication date
JPH06102655B2 (ja) 1994-12-14
NZ207358A (en) 1987-03-06
GB8405805D0 (en) 1984-04-11
GB8610648D0 (en) 1986-06-04
DK170647B1 (da) 1995-11-20
IL71143A (en) 1988-07-31
SU1442076A3 (ru) 1988-11-30
ES8602840A1 (es) 1985-12-01
FI840890A (fi) 1984-09-11
DK190590D0 (da) 1990-08-10
PT78181B (en) 1986-08-05
US4808614A (en) 1989-02-28
DK162529B (da) 1991-11-11
GR81845B (fr) 1984-12-12
PH23593A (en) 1989-09-11
FI77870C (fi) 1989-05-10
ES530364A0 (es) 1985-12-01
DE3466224D1 (en) 1987-10-22
NL950018I1 (fr) 1995-11-01
UA5955A1 (uk) 1994-12-29
DK190590A (da) 1990-08-10
BG40814A3 (en) 1987-02-16
PH23240A (en) 1989-06-06
US4692434A (en) 1987-09-08
GB2136425B (en) 1987-05-13
FI77870B (fi) 1989-01-31
GB2136425A (en) 1984-09-19
IE840584L (en) 1984-09-10
AR243533A1 (es) 1993-08-31
DK114484D0 (da) 1984-02-28
JPS59175498A (ja) 1984-10-04
DD216468A5 (de) 1984-12-12
HK44989A (en) 1989-06-09
EP0122707B1 (fr) 1987-09-16
CA1218647A (fr) 1987-03-03
AU565856B2 (en) 1987-10-01
CA1223869A (fr) 1987-07-07
MX9203246A (es) 1992-07-31
ZA841605B (en) 1985-10-30
RO89963A (fr) 1986-09-30
PL142437B1 (en) 1987-10-31
JPH0542438B2 (fr) 1993-06-28
KE3874A (en) 1989-06-30
DK162529C (da) 1992-03-30
PL246601A1 (en) 1985-08-13
US5118820A (en) 1992-06-02
GB2172287B (en) 1987-05-20
DK114484A (da) 1984-09-11
IL80463A0 (en) 1987-01-30
LU88791I2 (fr) 1996-11-05
DE19675003I2 (de) 2003-05-22
PT78181A (en) 1984-04-01
EP0122707A1 (fr) 1984-10-24
ATE29726T1 (de) 1987-10-15
JPH069602A (ja) 1994-01-18
KR860001283B1 (ko) 1986-09-05
US5015743A (en) 1991-05-14
US4526988A (en) 1985-07-02
GB2172287A (en) 1986-09-17
IL80463A (en) 1988-07-31
FI840890A0 (fi) 1984-03-06
HU193893B (en) 1987-12-28
AU2537484A (en) 1984-09-13
CS246075B2 (en) 1986-10-16
SG21889G (en) 1989-07-14
KR840007883A (ko) 1984-12-11
NL950018I2 (nl) 1997-03-03
IL71143A0 (en) 1984-06-29
IE57071B1 (en) 1992-04-22
MY102025A (en) 1992-02-29

Similar Documents

Publication Publication Date Title
DE3466224D1 (en) Improvements in or relating to novel difluoro antiviral agents
GB2117703B (en) Improvements in or relating to fire-barriers
GB2125649B (en) Improvements in or relating to rangefinders
IL70075A0 (en) Improvements in or relating to 3-aryl-5-pyrazole derivatives
GB2151768B (en) Improvements in or relating to combustors
DE3470782D1 (en) Improvements in or relating to cable-and-sleeve connectors
KE3768A (en) Improvements in or relating to carriers
GB2155654B (en) Improvements in or relating to eyeguards
GB8817519D0 (en) Improvements in/relating to ladders
HK2090A (en) Improvements in or relating to cyanopyrazole herbicides
GB2126041B (en) Improvements in or relating to rangefinders
GB2145899B (en) Improvements in or relating to telecines
GB2134577B (en) Improvements in or relating to roadsigns
GB2118587B (en) Improvements in or relating to structures
GB2100303B (en) Improvements in or relating to cardclothing
GB2122785B (en) Improvements in or relating to counter circuits
GB2150570B (en) Novel antiviral agents
GB2144570B (en) Improvements in or relating to display devices
GB2210190B (en) Improvements in or relating to ticketing
GB2146768B (en) Improvements in or relating to surveying techniques
GB2143272B (en) Improvements in or relating to scaffolding
ZA84628B (en) Improvements in or relating to hydro-cyclones
GB2179774B (en) Improvements in or relating to prescalers
GB2139873B (en) Improvements in or relating to ear-rings
IL68500A0 (en) Improvement in or relating to naphthalenamine derivatives